Assertio (ASRT) Q3 2024 earnings summary

Executive summary

• Q3 2024 net product sales were $28.7 million, with Rolvedon contributing $15.0 million and Indocin $5.7 million, reflecting a shift from Indocin to Rolvedon as the lead product.

• Net loss for Q3 2024 was $2.9 million, a significant improvement from a $279.5 million loss in Q3 2023, which included a $238.8 million impairment charge.

• Cash and short-term investments totaled $88.6 million at quarter end, with debt unchanged at $40 million.

• Board leadership transitioned: Peter Staple retired, Heather Mason appointed Chair, and David Stark joined as independent director.

• The company addressed and refuted public allegations, affirming product safety and integrity of financial disclosures.

Financial highlights

• Q3 2024 total product sales were $28.7 million, down from $30.7 million in Q2 and $35.1 million in Q3 2023, mainly due to lower Indocin sales.

• Rolvedon sales were $15.0 million in Q3, nearly flat sequentially and up from $7.1 million in Q3 2023; Indocin sales declined to $5.7 million from $17.9 million in Q3 2023.

• Gross margin improved to 74% in Q3 2024 from 71% in Q2, driven by lower inventory write-downs and product mix.

• GAAP net loss was $2.9 million, improved from a $3.7 million loss in Q2; adjusted EBITDA rose to $5.3 million from $5.0 million in Q2.

• Cash and short-term investments at quarter-end were $88.6 million; debt was $40 million in 6.5% convertible notes due 2027.

Outlook and guidance

• Maintaining existing guidance range for the year due to ongoing market and pricing uncertainties.

• Rolvedon growth is planned for 2025 as expansion moves beyond clinics into hospitals, with same-day dosing trial results to be presented at a major symposium.

• Focus remains on steady execution, cash flow generation, and identifying new assets for acquisition.

• Rolvedon average selling price expected to remain under pressure due to higher discounts and rebates.

• Management expects existing cash and investments to fund operations and debt payments for at least the next 12 months.